Glycoengineering of Natural Killer Cells with CD22 Ligands for Enhanced Anticancer Immunotherapy
Open Access
- 5 March 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 6 (3) , 382-389
Abstract
Adoptive transfer of immune cells is being actively pursued for cancer treatment. Natural killer (NK) cells, a class of cytotoxic immune cells, generally lack inherent selectivities toward cancer. To bestow tumor-targeting abilities and enhance anticancer efficacy, a new strategy is established to glycoengineer NK cells. Carbohydrate-based ligands for CD22, a marker for B cell lymphoma, are introduced onto NK cells through either metabolic engineering or glyco-polymer insertion. Such NK cells exhibited greatly enhanced cytotoxicities toward CD22+ lymphoma cells in a CD22-dependent manner. Importantly, both CD22+ lymphoma cell lines and primary lymphoma cells from human cancer patients can be effectively killed by the engineered NK cells. Furthermore, glycoengineered NK cells provided significant protection to tumor-bearing mice. Thus, NK cell glycoengineering is an exciting new approach for cancer treatment complementing the current immune cell genetic engineering strategy.Keywords
Funding Information
- National Cancer Institute (R01CA225105)
- Michigan Economic Development Corporation
- Michigan State University
- Xiamen Nuokangde Biological Technology Co., Ltd
This publication has 36 references indexed in Scilit:
- Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patientsBlood, 2011
- Antigen Specific In Vivo Killing Assay using CFSE Labeled Target CellsJournal of Visualized Experiments, 2010
- In vivo targeting of B-cell lymphoma with glycan ligands of CD22Blood, 2010
- NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effectsBlood, 2010
- Metabolic glycoengineering: Sialic acid and beyondGlycobiology, 2009
- Newer monoclonal antibodies for hematological malignanciesExperimental Hematology, 2008
- A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's LymphomaAnnual Review of Medicine, 2008
- Monoclonal Antibodies for B-Cell Lymphomas: Rituximab and BeyondHematology-American Society Hematology Education Program, 2007
- Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancerBlood, 2005
- The Ligand-binding Domain of CD22 Is Needed for Inhibition of the B Cell Receptor Signal, as Demonstrated by a Novel Human CD22-specific Inhibitor CompoundJournal of Experimental Medicine, 2002